Latest news with #proteomics
Globe and Mail
2 days ago
- Business
- Globe and Mail
Biochips Market Projected to Reach USD 37.73 Bn by 2032, Growing at 16.0% CAGR
Biochips Market, By Product Type (DNA Chips, Protein Chips, Lab-on-chip Tissue Arrays, Cell Arrays), By End User (Biotechnology and Pharmaceutical Companies, Academic & Research Institutes, Hospitals and Diagnostic Centers, Others), By Geography (North America, Latin America, Europe, Asia Pacific, Middle East & Africa) According to a recent report by Coherent Market Insights, Global Biochips market is estimated to be valued at USD 13.34 Bn in 2025 and is expected to reach USD 37.73 Bn by 2032, exhibiting a compound annual growth rate (CAGR) of 16.0% from 2025 to 2032. Increasing application of biochips in the field of proteomics, genomics and drug discovery can drive the market growth. Extensive R&D activities in the field of healthcare and growing demand for point-of-care testing and diagnostics can also boost demand for biochips during the forecast period. Global Biochips Market Key Takeaways According to Coherent Market Insights (CMI), the global biochips market size is projected to grow at a robust CAGR of 16%, from USD 13.34 Bn in 2025 to USD 37.73 Bn by 2032. Based on product type, DNA chips segment is expected to account for over two-fifths of the global biochips market in 2025. By end user, biotechnology and pharmaceuticals segment will likely hold a market share of 35.1% by 2025. North America is anticipated to retain its dominance, holding a market share of nearly 2/5 in 2025. As per CMIs' new biochips market analysis, Asia Pacific is expected to experience fastest growth during the forecast period. Growing Demand for Personalized Medicine Boosting Market Growth Coherent Market Insights' latest biochips market research report highlights major factors driving industry growth. One such prominent growth factor is the increasing demand for personalized medicine. Biochips are a key enabling technology in personalized medicine. They enable rapid and accurate analysis of an individual's genetic and proteomic profiles. This supports pharmacogenomics, helps in creating tailored treatment plans, and facilitates targeted therapies. These capabilities are especially valuable in managing complex diseases such as cancer. Thus, growing interest in personalized medicine will continue to provide a strong impetus for the growth of biochips market in the coming years. High Cost of Biochips and Adoption of Alternative Technologies Limiting Market Growth The future biochips market outlook looks promising. However, high cost of bioships and associated equipment, along with growing usage of alternative technologies, remain a significant barrier to broader market growth. Biochips are quite expensive due to their complex manufacturing processes and the need for specialized instrumentation. This high cost limits their accessibility, particularly among small and mid-sized laboratories, thereby reducing overall biochips market demand. Many end users are turning to alternative technologies like immunoassays, qPCR, and next-generation sequencing (NGS) due to their accuracy and cost-efficiency. This trend may also negatively impact the biochips market growth in the coming years. Growing Adoption in Disease Diagnostics Creating Lucrative Growth Opportunities Biochips are being increasingly used in the diagnosis of cancer, genetic disorders, and infectious diseases due to their high accuracy and speed. Their rising adoption in disease diagnostics is expected to create lucrative growth opportunities for biochip manufacturers during the forecast period. Rising incidence of chronic and infectious diseases, such as COVID-19, is creating a strong need for rapid diagnostics. This is expected to drive demand for biochips, as they offer fast and multiplexed detection of pathogens, making them ideal for point-of-care testing. Get Up to 25% Discount on the US Tariff Impact Analysis Report: Impact of AI on the Biochips Market Artificial Intelligence (AI) is making a profound impact on the biochips market. It enhances data analysis, diagnostics, and personalized medicine. AI algorithms significantly improve the accuracy and speed of disease detection by rapidly interpreting complex biological data produced by biochips. This powerful combination accelerates drug discovery and enables real-time health monitoring. With ongoing advancements in AI, new applications and efficiencies are expected to emerge. This evolution is poised to propel the biochips market toward greater scalability and precision in delivering advanced healthcare solutions. Emerging Biochips Market Trends Growing trend of miniaturization is significantly impacting the biochips market value. Key manufacturers are focusing on developing compact biochips (e.g. lab-on-a-chip systems) with improved features for use in diagnostics, drug discovery, and personalized medicine. Expanding applications of biochips in drug discovery is expected to foster sales growth. Biochips are increasingly used in drug discovery processes, particularly for gene expression analysis, toxicity profiling, and target identification. These applications are crucial for accelerating pharmaceutical R&D, thereby driving market growth. There is a growing emphasis on studying genes and proteins to better understand disease mechanisms, identify potential therapeutic targets, and develop personalized medicine approaches. This will likely create a strong demand for biochips in high-throughput research. Shift toward point-of-care testing (POCT) is expected to create lucrative growth avenues for biochip companies. Portable biochips are being widely used in POCT devices for faster diagnostics at the patient's location. Ongoing advancements in biochip manufacturing will also support market expansion. Improvements in microfluidics, microarray technology, and semiconductor biochip development are significantly enhancing capabilities of biochips. Analyst's View ' The global biochips market is expected to record robust growth, owing to increasing incidence of chronic and infectious diseases, rising demand for personalized medicines, and advancements in biochip manufacturing,' said senior analyst Abhijeet Kale. Current Events and Their Impact on the Biochips Market Competitor Insights Key companies listed in biochips market report: - LinguaFlex - Inspire Medical Systems, Inc. - Medtronic - LivaNova PLC - SomnoMed - Nihon Kohden Corporation - Siesta Medical Inc. - ResMed - Koninklijke Philips N.V. - Somnowell - Nyxoah SA - Fisher & Paykel Healthcare Limited - VYAIRE - Natus Medical Incorporated - Nox Medical - Drive DeVilbiss International - CLEVELAND MEDICAL DEVICES INC. - Advanced Brain Monitoring, Inc. - CONTEC MEDICAL SYSTEMS CO., LTD Key Developments In January 2025, Coherent Corp launched its new pinhole array biochips. These biochips are specifically designed for medical diagnostics, with a strong focus on gene sequencing applications. In May 2025, Archer Materials Limited partnered with Paragraf Limited for Biochip development. This partnership is intended to help Archer advance its Biochip for at-home testing of chronic kidney disease. Market Segmentation By Product Type DNA Chips Cancer Diagnosis and Treatment Gene Expression SNP Genotyping Genomics Drug Discovery Agricultural Biotechnology Others Protein Chips Proteomics Expression Profiling Diagnostics HTS Others Lab-on-chip IVD & POC Others Tissue Arrays Cell Arrays By End User Biotechnology and Pharmaceutical Companies Academic & Research Institutes Hospitals and Diagnostic Centers Others About Us:Coherent Market Insights leads into data and analytics, audience measurement, consumer behaviors, and market trend analysis. From shorter dispatch to in-depth insights, CMI has exceled in offering research, analytics, and consumer-focused shifts for nearly a decade. With cutting-edge syndicated tools and custom-made research services, we empower businesses to move in the direction of growth. We are multifunctional in our work scope and have 450+ seasoned consultants, analysts, and researchers across 26+ industries spread out in 32+ countries. Media Contact Company Name: Coherent Market Insights Contact Person: Mr. Shah Email: Send Email Phone: + 12524771362 Address: 533 Airport Boulevard, Suite 400, Burlingame, CA 94010, United States Burlingame City: Burlingame State: California Country: United States Website:
National Post
02-06-2025
- Business
- National Post
SCIEX and Evosep expand access to standardized proteomics for Pharma and Biotech with new reseller agreement
Article content MARLBOROUGH, Mass. — SCIEX, a global leader in life science analytical technologies and operating company of Danaher Corporation (NYSE: DHR), and Evosep Biosystems, a global leader in proteomics solutions, enter a reseller agreement to co-sell SCIEX mass spectrometry systems with the newly announced Evosep Eno, for standardized high-throughput proteomics. Article content Article content The reseller agreement empowers researchers to implement standardized proteomics workflows, delivering a robust LC-MS solution designed to meet the evolving demands of pharmaceutical and biotech companies. With Evosep Eno, researchers gain exceptional throughput, sensitivity, and reproducibility. When combined with SCIEX mass spectrometers—engineered for speed and sensitivity in both quantitative and qualitative analyses—this collaboration ensures access to cutting-edge technology tailored to today's analytical challenges. Article content The latest research from SCIEX and Evosep, shows that the Evosep Eno provides an >5-fold increase of peptide precursor identifications and an >3-fold increase of protein group identifications, at 500 SPD, when coupled to the new ZenoTOF 8600 system. This enables a greater depth of proteome coverage for large-scale cohort, high-throughput analysis. Article content 'For the application of proteomics in translational medicine, this extended collaboration between SCIEX and Evosep will further adoption of standardized solutions and make the technology more accessible—even to those new to proteomics,' said Morten Bern, CEO of Evosep. 'Together, we have an exciting opportunity to make a meaningful impact through LC-MS–based proteomics by combining our strengths to deliver solutions that ultimately enhance patient care and improve quality of life.' Article content 'Our collaboration with Evosep over the years has allowed us to continue to advance and standardize high throughput proteomics workflows. It is exciting to see the exceptional performance for the quantitative identification of peptides and proteins in complex samples. We are committed to providing the best solution for our customers,' said Jose Castro-Perez Ph.D., Vice president of product management at SCIEX. Article content This agreement allows users to access SCIEX mass spectrometry systems and the Evosep Eno via a single product catalogue issued by SCIEX. This option is available to customers located in the USA, Canada, Germany, France, Italy, Switzerland, Austria, Spain, Portugal, Sweden, Norway, Denmark, Finland, Belgium, Netherlands, Latvia, Lithuania, Estonia, and Luxembourg. Both vendors commit to deliver coordinated service and leading analytical performance. SCIEX will support the full customer relationship and Evosep will provide direct UHPLC service and support. Article content SCIEX empowers our customers to solve the most impactful analytical challenges in quantitation and characterization. With groundbreaking innovation and outstanding reliability and support, SCIEX has been at the forefront of the field for over 50 years. Article content Since the launch of the first-ever commercially successful triple quadrupole in 1981, we continue to develop technologies and solutions that influence life-changing research and outcomes. That's why thousands of life science experts around the world choose SCIEX to get the answers they can trust. Article content Advances in human wellness depend on the power of precise science. Article content SCIEX is proud to be part of Danaher. Article content Danaher's science and technology leadership puts SCIEX solutions at the forefront of the industry, so they can reach more people. Being part of Danaher means we can offer unparalleled breadth and depth of expertise and solutions to our customers. Together with Danaher's other businesses across Biotechnology, Diagnostics and Life Sciences, we unlock the transformative potential of cutting-edge science and technology to improve billions of lives every day. Article content The SCIEX clinical diagnostic portfolio is for in vitro Diagnostic Use. Rx Only. Product(s) not available in all countries. For information on availability, please contact your local sales representative or refer to All other products are For Research Use Only. Not for use in Diagnostic Procedures. Article content Trademarks and/or registered trademarks mentioned herein, including associated logos, are the property of AB Sciex Pte. Ltd. or their respective owners in the United States and/or certain other countries (see Article content Article content Article content Article content
Associated Press
01-06-2025
- Health
- Associated Press
Seer's Proteograph Platform Enables Unprecedented 20,000-Sample Proteomics Study with Korea University to Develop AI-Driven Diagnostics for Cancers in Young Adults
First-of-its-kind study will use Seer's next-generation workflow to identify early-onset cancer biomarkers and power deep, unbiased mass spectrometry-based proteomics Seer's new Proteograph ONE Assay to accelerate analysis and reduce costs, making large-scale studies feasible REDWOOD CITY, Calif., June 01, 2025 (GLOBE NEWSWIRE) -- Seer, Inc. (Nasdaq: SEER), the pioneer and trusted partner for deep, unbiased proteomic insights, and Korea University, a leading research institution committed to innovation and global impact, today announced the launch of a population-level study aimed at identifying novel blood-based biomarkers that could lead to cancer diagnostics for young adults in their 20s and 30s. Relying on Seer's newly launched Proteograph® ONE Assay and SP200 Automation Instrument along with the Thermo Scientific™ Orbitrap™ Astral™ mass spectrometer, this is the first large-scale plasma proteomics initiative of its kind to leverage mass spectrometry and AI-driven analytics to enhance early cancer detection and improve patient outcomes. Seer's latest platform advances will allow deep, unbiased proteomic analysis of 20,000 plasma samples in less time and cost than has ever before been possible. These will include samples from 15,000 cancer patients and 5,000 healthy patients that will serve as controls, sourced from Korea's leading cancer institutions: Seoul National University Hospital, the National Cancer Center, and Samsung Medical Center. The three-year study is funded by the K-Health MIRAE initiative under the Ministry of Health and Welfare, Republic of Korea, which supports ambitious, high-impact health research. 'We carefully evaluated multiple approaches to expand the dynamic range of the plasma proteome—including some attempting to replicate Seer's Proteograph platform—and Seer's assay stood out as the only solution capable of delivering the depth, scale, and, critically, reproducibility needed for this ambitious study,' said Professor Sang-Won Lee at the Center of Proteogenome Research (CPGR) of Korea University. 'The unique combination of Seer's latest platform and CPGR's proprietary dual online liquid chromatography technology gives us the ability to conduct population-scale research that would otherwise be prohibitively complex and slow. This collaboration represents a major step toward developing AI-powered diagnostics that could fundamentally improve how we detect and treat cancer in younger adults.' By leveraging the power of deep proteomic analysis, this study aims to catalyze a new wave of diagnostics that are more sensitive, scalable, and personalized—ultimately driving earlier interventions and improving survival outcomes in young adult cancer patients worldwide. Transformational Technology for Population-Scale Proteomics At the heart of the study is Seer's Proteograph ONE workflow, introduced this week at the 2025 American Society for Mass Spectrometry (ASMS) Conference in Baltimore, MD. The next-generation system dramatically increases scale and efficiency in proteomic analysis by: 'Korea University selected Seer's new Proteograph ONE workflow as the foundation for this critical and forward-looking initiative so that they can unlock the full potential of proteomics in population-scale research,' said Omid Farokhzad, Chair and CEO of Seer. 'We're excited to help define a new generation of diagnostics that can transform how diseases like cancer are detected and managed around the world.' The study also employs Thermo Scientific's Orbitrap Astral MS—the industry's leading mass spectrometer for proteomic research. The Proteograph offerings combined with the Orbitrap Astral MS provide a deep, full-range plasma proteome analysis at faster speeds to enable critical breakthrough discoveries in large-population studies. 'When it comes to plasma proteomics studies such as this, the Orbitrap Astral MS and Proteograph ONE workflow provide a powerful solution to drive groundbreaking research,' said Dan Shine, senior vice president and president of analytical instruments, Thermo Fisher Scientific. 'We're proud to be a part of initiatives like this to enable earlier detection and help progress precision medicine.' The next-generation offerings mark a significant evolution of the Proteograph Product Suite, delivering the scale, speed, and efficiency required to make population-level proteomics both practical and accessible. The collaboration with Korea University exemplifies the real-world impact of this technology—demonstrating how deep, unbiased proteomic insights powered by Seer's platform can now inform large-scale studies, accelerate biomarker discovery, and drive the development of AI-enabled diagnostics that redefine precision medicine. About Seer, Inc. Seer, Inc. (Nasdaq: SEER) sets the standard in deep, unbiased proteomics—delivering insights with a scale, speed, precision, and reproducibility previously unattainable. Seer's Proteograph Product Suite uniquely integrates proprietary engineered nanoparticles, streamlined automation instrumentation, optimized consumables, and advanced analytical software to solve challenges conventional methods have failed to overcome. Traditional proteomic technologies have struggled with inconsistent data, limited throughput, and prohibitive complexity, but Seer's robust and scalable workflow consistently reveals biological insights that others cannot. Seer's products are for research use only and are not intended for diagnostic procedures. For more information about Seer's differentiated approach and ongoing leadership in proteomics, visit Media Contact: Consort Partners [email protected] Investor Contact: Carrie Mendivil [email protected]
Yahoo
01-06-2025
- Health
- Yahoo
Seer's Proteograph Platform Enables Unprecedented 20,000-Sample Proteomics Study with Korea University to Develop AI-Driven Diagnostics for Cancers in Young Adults
First-of-its-kind study will use Seer's next-generation workflow to identify early-onset cancer biomarkers and power deep, unbiased mass spectrometry-based proteomics Seer's new Proteograph ONE Assay to accelerate analysis and reduce costs, making large-scale studies feasible REDWOOD CITY, Calif., June 01, 2025 (GLOBE NEWSWIRE) -- Seer, Inc. (Nasdaq: SEER), the pioneer and trusted partner for deep, unbiased proteomic insights, and Korea University, a leading research institution committed to innovation and global impact, today announced the launch of a population-level study aimed at identifying novel blood-based biomarkers that could lead to cancer diagnostics for young adults in their 20s and 30s. Relying on Seer's newly launched Proteograph® ONE Assay and SP200 Automation Instrument along with the Thermo Scientific™ Orbitrap™ Astral™ mass spectrometer, this is the first large-scale plasma proteomics initiative of its kind to leverage mass spectrometry and AI-driven analytics to enhance early cancer detection and improve patient outcomes. Seer's latest platform advances will allow deep, unbiased proteomic analysis of 20,000 plasma samples in less time and cost than has ever before been possible. These will include samples from 15,000 cancer patients and 5,000 healthy patients that will serve as controls, sourced from Korea's leading cancer institutions: Seoul National University Hospital, the National Cancer Center, and Samsung Medical Center. The three-year study is funded by the K-Health MIRAE initiative under the Ministry of Health and Welfare, Republic of Korea, which supports ambitious, high-impact health research. 'We carefully evaluated multiple approaches to expand the dynamic range of the plasma proteome—including some attempting to replicate Seer's Proteograph platform—and Seer's assay stood out as the only solution capable of delivering the depth, scale, and, critically, reproducibility needed for this ambitious study,' said Professor Sang-Won Lee at the Center of Proteogenome Research (CPGR) of Korea University. 'The unique combination of Seer's latest platform and CPGR's proprietary dual online liquid chromatography technology gives us the ability to conduct population-scale research that would otherwise be prohibitively complex and slow. This collaboration represents a major step toward developing AI-powered diagnostics that could fundamentally improve how we detect and treat cancer in younger adults.' By leveraging the power of deep proteomic analysis, this study aims to catalyze a new wave of diagnostics that are more sensitive, scalable, and personalized—ultimately driving earlier interventions and improving survival outcomes in young adult cancer patients worldwide. Transformational Technology for Population-Scale Proteomics At the heart of the study is Seer's Proteograph ONE workflow, introduced this week at the 2025 American Society for Mass Spectrometry (ASMS) Conference in Baltimore, MD. The next-generation system dramatically increases scale and efficiency in proteomic analysis by: Processing 1,000+ samples per week per instrument Requiring only a single mass spectrometry injection per sample Completing 80-sample batches with <5 hours automated runtime Identifying up to 10 times more proteins than conventional mass spectrometry methods 'Korea University selected Seer's new Proteograph ONE workflow as the foundation for this critical and forward-looking initiative so that they can unlock the full potential of proteomics in population-scale research,' said Omid Farokhzad, Chair and CEO of Seer. 'We're excited to help define a new generation of diagnostics that can transform how diseases like cancer are detected and managed around the world.' The study also employs Thermo Scientific's Orbitrap Astral MS—the industry's leading mass spectrometer for proteomic research. The Proteograph offerings combined with the Orbitrap Astral MS provide a deep, full-range plasma proteome analysis at faster speeds to enable critical breakthrough discoveries in large-population studies. 'When it comes to plasma proteomics studies such as this, the Orbitrap Astral MS and Proteograph ONE workflow provide a powerful solution to drive groundbreaking research,' said Dan Shine, senior vice president and president of analytical instruments, Thermo Fisher Scientific. 'We're proud to be a part of initiatives like this to enable earlier detection and help progress precision medicine.' The next-generation offerings mark a significant evolution of the Proteograph Product Suite, delivering the scale, speed, and efficiency required to make population-level proteomics both practical and accessible. The collaboration with Korea University exemplifies the real-world impact of this technology—demonstrating how deep, unbiased proteomic insights powered by Seer's platform can now inform large-scale studies, accelerate biomarker discovery, and drive the development of AI-enabled diagnostics that redefine precision medicine. About Seer, Inc. Seer, Inc. (Nasdaq: SEER) sets the standard in deep, unbiased proteomics—delivering insights with a scale, speed, precision, and reproducibility previously unattainable. Seer's Proteograph Product Suite uniquely integrates proprietary engineered nanoparticles, streamlined automation instrumentation, optimized consumables, and advanced analytical software to solve challenges conventional methods have failed to overcome. Traditional proteomic technologies have struggled with inconsistent data, limited throughput, and prohibitive complexity, but Seer's robust and scalable workflow consistently reveals biological insights that others cannot. Seer's products are for research use only and are not intended for diagnostic procedures. For more information about Seer's differentiated approach and ongoing leadership in proteomics, visit Media Contact:Consort Partnerspr@ Investor Contact:Carrie Mendivilinvestor@ in to access your portfolio
Yahoo
26-05-2025
- Business
- Yahoo
Proteomics Market Global and Regional Analysis and Forecasts, 2024-2025 & 2034: Increasing Automation for End-to-End Proteomics Workflow, Significant Number of Collaborations Among Market Players
Key growth catalysts include advancements in mass spectrometry and next-generation sequencing, heightened demand for personalized medicine, increased research funding, and strategic collaborations. With applications in drug discovery, diagnostics, and personalized medicine, the market is expanding rapidly across regions, particularly in Asia-Pacific, fueled by significant healthcare and biotech investments. Notable players include Danaher, Thermo Fisher, and Agilent Technologies, all focusing on innovative solutions. Proteomics Market Dublin, May 26, 2025 (GLOBE NEWSWIRE) -- The "Proteomics Market - A Global and Regional Analysis: Focus on Offerings, Application, End User, and Region - Analysis and Forecast, 2024-2034" report has been added to global proteomics market is projected to reach $109.71 billion by 2034 from $33.92 billion in 2024, growing at a CAGR of 12.46% during the forecast period 2024-2034. Key factors driving this growth include technological advancements in mass spectrometry and next-generation sequencing, which improve the accuracy of proteomics analysis. The rising demand for personalized medicine, particularly for biomarker discovery and disease profiling, is another major driver. Additionally, increased research funding, strategic collaborations, and the need for early disease detection and effective diagnostics further support market expansion. With an aging population and a higher prevalence of chronic diseases, the demand for proteomics in healthcare and research is expected to continue to rise, ensuring the market sustained growth. Proteomics has significantly advanced disease understanding by uncovering molecular mechanisms in conditions like cancer, cardiovascular, and neurological disorders. It plays a vital role in biomarker discovery, enabling early, precise, and non-invasive diagnostics. In personalized medicine, proteomics supports tailored treatment strategies based on individual protein profiles. The field also aids drug development by identifying new targets and facilitating the study of protein-therapeutic interactions. Clinically, proteomics improves disease monitoring, treatment planning, and therapeutic assessments. Additionally, it drives technological innovation in analytical tools such as mass spectrometry and protein arrays, influencing broader scientific market is expanding in regions such as North America, Europe, Asia-Pacific, Latin America, the Middle East, and Africa, with Asia-Pacific experiencing rapid growth due to increasing investments in healthcare and biotechnology. Together, these elements drive the continued evolution and growth of the proteomics market globally. China dominated the Asia-Pacific proteomics market in 2022, driven by several key factors. The country has made substantial investments in healthcare, biotechnology, and life sciences research, positioning itself as a leader in the region. China robust infrastructure, large population, and government initiatives, such as the ""Made in China 2025 plan, which emphasizes technological innovation, have further accelerated advancements in proteomics addition, China has become a hub for pharmaceutical and biotechnology companies, fostering an environment conducive to research and development in areas such as drug discovery, personalized medicine, and biomarker identification. The growing demand for proteomics in clinical diagnostics, coupled with the country increasing focus on precision medicine, has bolstered market the rapid adoption of advanced proteomics technologies, such as mass spectrometry and next-generation sequencing, has allowed China to expand its research capabilities and enhance its position in the global market. With a strong emphasis on improving healthcare outcomes and expanding its scientific capabilities, China is expected to continue to lead the proteomics market in the Asia-Pacific region for the foreseeable future. Market Segmentation Highlights Based on offering, the proteomics market is led by product, which held a 72.53% share in 2022. Based on application, the proteomics market is led by drug discovery, which held a 53.64% share in 2022. Based on end user, the proteomics market is led by academic and research institutions, which held a 51.50% share in 2022. Key Market Players Danaher Corporation Thermo Fisher Scientific, Inc. Agilent Technologies, Inc. Bio-rad Laboratories Revvity, Inc. Illumina, Inc. DiaSorin S.p.A. Takara Bio Inc. Merck KGaA Key Attributes: Report Attribute Details No. of Pages 176 Forecast Period 2024 - 2034 Estimated Market Value (USD) in 2024 $33.92 Billion Forecasted Market Value (USD) by 2034 $109.71 Billion Compound Annual Growth Rate 12.4% Regions Covered Global Key Topics Covered: Executive SummaryScope and Definition1 Market1.1 Market Outlook1.1.1 Comparative Advantages and Disadvantages of Proteomics Over Other Omics1.1.2 Proteomics Techniques by Introduction with Principles and Advantages/Limitations1.2 Key Findings1.3 Proteomics Market Scenario1.3.1 Realistic Scenario1.3.2 Optimistic Scenario1.3.3 Pessimistic Scenario1.4 Industry Outlook1.4.1 Supply Chain Overview1.5 Trends: Current and Future Impact Assessment1.5.1 Increasing Automation for End-to-End Proteomics Workflow1.5.2 Significant Number of Collaborations among Market Players1.5.3 Growing Proteomics Research to Identify Disease Biomarkers1.6 Patent Analysis1.6.1 Patent Filing Trend (by Country, Year)1.7 Regulatory Framework1.7.1 U.S.1.7.1.1 Regulatory Requirements for Proteomics Products Intended as Medical Devices1.7.1.2 Regulatory Requirements for Research Use Only (RUO) Products1.7.1.3 Requirements under the Clinical Laboratory Improvement Amendments (CLIA) for Clinical Proteomics Labs1.7.2 European Union (EU)1.7.2.1 Regulatory Requirements for Proteomics Products Intended as Medical Devices1.7.2.1.1 EU Medical Device Regulation1.7.2.1.2 EU In Vitro Diagnostic Regulation1.7.2.2 Regulatory Requirements for Clinical Proteomics Labs in the EU1.7.3 Japan1.7.3.1 Regulatory Requirements for Proteomics Products Intended as Medical Devices1.7.3.2 Regulatory Requirements for Clinical Proteomics Labs in Japan1.7.4 China1.7.4.1 Regulatory Requirements for Proteomics Products Intended as Medical Devices1.7.5 Brazil1.7.5.1 Regulatory Requirements for Proteomics Products Intended as Medical Devices1.7.5.2 Regulatory Requirements for Clinical Proteomics Labs in Brazil1.8 Product Benchmarking1.9 Market Dynamics Overview1.9.1 Market Drivers1.9.1.1 Increasing Prevalence of Chronic Diseases1.9.1.2 Increasing Technological Advancements1.9.1.3 Advancements in Personalized Medicine and Drug Discovery1.9.2 Market Restraints1.9.2.1 Shortage of Skilled Professionals1.9.2.2 Complexity in Analyzing Data of Proteomics Research1.9.3 Market Opportunities1.9.3.1 Progress in Nanoproteomics Platforms to Enhance and Thoroughly Analyze Natural Protein Complexes2 Global Proteomics Market (by Offering), $Million, 2022-20342.1 Product2.1.1 Kits and Reagents2.1.2 Instruments2.1.2.1 Spectroscopy2.1.2.2 Chromatography2.1.2.3 Electrophoresis2.1.2.4 Others2.1.3 Software2.2 Service3 Global Proteomics Market (by Application), $Million, 2022-20343.1 Drug Discovery3.2 Clinical Diagnostics3.2.1 Cancer3.2.2 Infectious Disease3.2.3 Others3.3 Others4 Global Proteomics Market (by End User), $Million, 2022-20344.1 Biopharmaceutical Companies4.2 Academic and Research Institutions4.3 Hospitals and Diagnostic Laboratories4.4 Others5 Global Proteomics Market (by Region), $Million, 2022-20345.1 Regional Summary5.2 North America5.2.1 Regional Overview5.2.2 Driving Factors for Market Growth5.2.3 Factors Challenging the Market5.2.4 North America Proteomics Market, by Application5.2.5 North America Proteomics Market, by Offering5.2.5.1 North America Proteomics Market, by Product5.2.6 U.S.5.2.7 Canada5.3 Europe5.4 Asia-Pacific5.5 Latin America5.6 Middle East and Africa6 Global NGS in Proteomics Market6.1 NGS in Proteomics6.1.1 Purpose of NGS in Proteomics6.1.2 Application of NGS in Proteomics6.1.2.1 Advantages of NGS-based Proteomics6.1.2.2 Challenges in NGS-based Proteomics6.1.2.3 Future Trends of NGS in Proteomics6.1.3 NGS in Large-Scale Proteomics6.2 Market Sizing and Forecast6.2.1 By Application6.2.2 By End User7 Markets - Competitive Benchmarking & Company Profiles7.1 Global Proteomics Market: Competitive Landscape7.1.1 Corporate Strategies, January 2022-December 20247.1.2 Partnerships, Alliances, and Business Expansions7.1.3 Mergers and Acquisitions7.1.4 New Offerings7.2 Company Profiles7.2.1 Overview7.2.2 Top Products/Services7.2.3 Top Competitors7.2.4 Target Customers7.2.5 Key Personnel7.2.6 Analyst View Agilent Technologies, Inc. Applied Biomics Biognosys AG Bio-Rad Laboratories, Inc. Danaher Corporation DiaSorin S.p.A. Illumina, Inc. Merck KGaA MS Bioworks Promega Corporation Oxford Expression Technologies Ltd. Revvity, Inc. Standard BioTools Inc. Takara Bio Inc. Thermo Fisher Scientific Inc. For more information about this report visit About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. Attachment Proteomics Market CONTACT: CONTACT: Laura Wood,Senior Press Manager press@ For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
